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Immortaltumorcell lines areanimportantmodelsystem forcancer research, however,misidentiﬁcationandcross-contamination
of cell lines are a common problem. Seven chordoma cell lines are reported in the literature, but none has been characterized in
detail. We analyzed gene expression patterns and genomic copy number variations in ﬁve putative chordoma cell lines (U-CH1,
CCL3, CCL4, GB60, and CM319). We also created a new chordoma cell line, U-CH2, and provided genotypes for cell lines for
identity conﬁrmation.Our analysesrevealed that CCL3, CCL4, and GB60 are not chordoma cell lines, and that CM319 is a cancer
cell linepossiblyderived from chordoma,but lackingexpressionofkeychordoma biomarkers.U-CH1 and U-CH2 both havegene
expression proﬁles, copy number aberrations, and morphology consistent with chordoma tumors. These cell lines also harbor
genetic changes, such as loss of p16, MTAP, or PTEN, that make them potentially useful models for studying mechanisms of
chordoma pathogenesis and for evaluating targeted therapies.
1.Introduction
Chordomasare rare, slow-growing, and locally invasive bone
tumors thought to be derived from notochordal remnants.
The anatomical distribution of these tumors mirrors the
location of notochord remnants, occurring most commonly
at either end of the axial skeleton (32% in the clivus
and 29% in the sacrum) [1]. Surgery is the mainstay of
chordoma management, and radiation is commonly used as
an adjuvanttherapy [2].Recurrence is common and ten-year
survival is only 39% [1]. Existing chemotherapies are usually
ineﬀective, making management of recurrences challenging
[3]. Improved systemic therapies are needed; however,
limited knowledge of the molecular genetics of chordoma,
a small patient population, and scarcity of preclinical data
have hampered eﬀorts to develop new treatments. There
are only two published clinical trials of systemic therapies
in chordoma; a phase II study of 9-nitro-camptothecin [4]
and a phase II study of imatinib [5]. Due to the challenge
of accruing patients from this small patient population,
preclinical data may need to be particularly supportive to
justify undertaking future clinical trials.
Immortalized tumor cell lines are an important cancer
biology research tool, and they can be useful in predicting
the clinical performance of cancer drugs [6, 7]. In par-
ticular, cell lines harboring certain drug targets present in
molecularly deﬁned cancer subtypes have proven valuable
in evaluating targeted agents. Recently, molecular features
that could indicate the application of targeted therapies
have been identiﬁed in chordoma, including activation
of the PI3K/Akt/mTOR pathway [8], activation of the
IGF1R signaling cascade [9], loss of methylthioadenosine
phosphorylase [9], and activation of STAT3 [10]. Chordoma
cell lines with similar molecular phenotypes are potentially
useful in preclinical evaluations of treatments that exploit
these potential therapeutic targets.2 Sarcoma
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Figure 1: Morphological appearance of putative chordoma cell lines in culture. Phase contrast photomicrographs of cultured CCL4B,
CM319, GB60, U-CH1, and U-CH2 show the chordoma tumor-like physaliphorous phenotype in only U-CH1 and U-CH2 cells.
Table 1: Publications of human chordoma cell lines and their growth media.
Cell line Reference
Obtained
from
author
Growth medium
U-CH1 [11]y e s IMDM/RPMI (4:1)
10% FBS collagen-coated ﬂasks
CM-319 [12]y e s RPMI 1640
10% FBS
GB60 [13]y e s DMEM/F12
10% FBS
(Unnamed in manuscript) [13]n o n / a
(Unnamed in manuscript) [13]n o n / a
CCL3 [14]y e s DMEM/F12
10% FBS
CCL4 [15]y e s DMEM/F12
10% FBS
U-CH2 Unpublished yes IMDM/RPMI (4:1)
10% FBS collagen-coated ﬂasks
K001 Unpublished yes IMDM/RPMI (4:1)
10% FBS collagen-coated ﬂasksSarcoma 3
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Figure 2: Gene expression analysis of chordoma tumors, putative chordoma cell lines, and normal tissues including intervertebral disk
(IVD).Five chordoma-speciﬁc genes from amongthe 2351 probe sets used forcluster analysisare included; T: brachyury, KRT19: keratin19,
Col2A1: collagen 2A1, CA3: carbonic anhydrase 3, and CD24. Genes with decreased relative expression are shown in green while those with
increased relative expressionareshowninred. Chordomatumors(ChordomaandChordoma-MK)andcell linesU-CH1, U-CH2, andK001
have similar expression patterns distinct from the other putative chordoma cell lines and other tissues.
There are several chordoma cell lines described in the
literature, but none have been fully characterized with state-
of-the-art molecular techniques to evaluate their suitability
as models of chordoma. Furthermore, these cell lines have
neverbeenindependentlyvalidated toconﬁrm theiridentity.
It is well known that cross-contamination and misidentiﬁ-
cation of cell lines are a widespread problem in molecular
cancer research [16, 17]. As many as one-third of cell lines
originate from a diﬀerent tissue or even species than claimed
[18–20]. Given the scarce resources available for research on
uncommon tumors, such as chordoma, the use ofinvalid cell
lines could be catastrophic to the ﬁeld. Therefore, character-
ization and validation of existing chordoma cell lines are of
great importance to translational chordoma research. In this4 Sarcoma
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Figure 3: Gene expression analysis of chordoma tumors, cell lines, and mesenchymal tumors. Five chordoma-speciﬁc genes from among
the 1208 probe sets used for cluster analysis are included; T: brachyury, KRT19: keratin19, Col2A1: collagen 2A1, CA3: carbonic anhydrase
3, and CD24. Genes with decreased relative expression are shown in green while those with increased relative expression are shown in red.
Chordomatumors(chordomaandchordoma-MK)andcell lines U-CH1, U-CH2, andK001 have a similarexpression patterns distinct from
the other putative chordoma cell lines and other tissues.Sarcoma 5
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Figure 4: Brachyury expression in putative chordoma cell lines. (a) Immunoblot analysis of Brachyury of CCL4B, CM319, GB60, U-CH1,
andU-CH2cellsrevealssigniﬁcantexpressionofthe ∼50kDaBrachyuryproteinonlyinU-CH1andU-CH2cells.Molecularweightstandard
laneisdenoted byM.(b)ImmunoﬂuorescentstainingforBrachyury revealed nuclearlocalizationoftheproteininbothU-CH1andU-CH2.
(c) Immunoblotanalysisofcytokeratin protein expression in CCL4,CM319, GB60,U-CH1, and U-CH2. (d) ImmunoblotanalysisofPTEN
protein expression in MRC-5 primary human ﬁbroblasts, U-CH1 and U-CH2. (e) Immunoblot analysis of activation of Akt in normal
human ﬁbroblasts (growing, serum starved for 48 hours then with, or without, 10% added serum for 45 minutes), U-CH1 and U-CH2.
Phospho-Akt- (Serine 473-) speciﬁc antibodies show Akt activation while similar protein loading was conﬁrmed by staining for total Akt
protein levels. For A, C, and E similar protein loading was conﬁrmed by staining for β-actin.
paper, we report our systematic characterization of cell lines
reported in theliterature thatclaimtobe ofchordoma origin
and establish a new chordoma cell line.
2.Methods
2.1. Cell Line Retrieval and Propagation. MEDLINE was
searched for all references to chordoma cell lines using the
search terms “chordoma cell line,” “chordoma cell culture,”
and “chordoma AND in vitro,” and each resulting article
was read to determine whether it described or reported
use of a chordoma cell line. The corresponding authors of
these publications were contacted, and a sample of each of
their chordoma cell lines was requested, whether published
or unpublished. Additionally, other unpublished chordoma
cell lines were solicited from attendees of the First (2007)
and Second (2008) International Chordoma Workshops and
through personal communication (JS) with researchers who
have published on chordoma and clinicians at medical
centers with a high volume of chordoma cases.
Once received, cells were grown to 90% conﬂuence
in 75cm2 tissue culture ﬂasks and passaged according
to methods described in their respective publications or
as communicated by the creators of the cell lines. The
culture media, serum, and substrate used for each cell line
are indicated in Table 1. All other lines were grown and
passaged using methods and medias as recommended by
the providers. Primary human cultures consisted of middle
passage MRC-5 (American Type Tissue Culture) derived
from human embryonic lung or NHF1, a gift from M.
Cordeiro-S‘tone, derived from newborn foreskin.
2.2. Establishment of New Cell Lines
2.2.1. U-CH2. Tumor tissue was obtained from a 72-year-
old female patient with recurrent sacral chordoma. The
cell line was established from tumor tissue obtained during
initial surgery without neoadjuvant treatment. The patient
provided informed consent. Clinical pathology determined
the tumor expressed EMA (clone E29, Dako, Glostrup, Den-
mark), vimentin (clone VIM3B4, Dako), cytokeratin (clone
AE1+AE2, Dako), and, to a minor degree, S100 protein
(polyclonal, Dako). The proliferation rate determined by
an anti-Ki-67 antibody (clone MIB-1, Dako) was between
5 and 10%. The tumor was minced, partially digested
with collagenase, and placed in collagen-coated Primaria
ﬂasks (Falcon, Becton-Dickinson, Heidelberg, Germany)
containing Iscove’s modiﬁed essential medium/RPMI 16406 Sarcoma
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Figure 6: Species analysis of putative chordoma cell lines. Agarose
gel electrophoresis of ethidium-stained DNA of aldolase PCR
analysis of genomic DNA reveals murine origin for CCL3 as
shown by similar amplicon fragment sizes found in the murine cell
line, NIH 3T3, as compared to those generated from the normal
humangenomicsample,CEPH1331-01.Theothercelllines(CCL4,
CM319, GB60, U-CH1, and U-CH2) gave similar amplicon sizes as
those for the human control genomic sample CEPH 1331-01.
medium (4:1) (Lonza, Verviers, Belgium) with 10% fetal
bovine serum (Biochrom AG, Berlin, Germany), 2mM glu-
tamine, and antibiotics (100U/mL penicillin G, 100mg/mL
streptomycin). Once the cells reached conﬂuence, they were
enzymatically detached using trypsin/EDTA (0.25%/0.02%,
Lonza). Cell populations with diﬀerential sensitivity to
trypsin/EDTA were separated by harvesting cells after vary-
ing incubation periods. Sequential separation of trypsin-
sensitive and trypsin-insensitive cells resulted in enrichment
of physaliferous cells in the trypsin-insensitive population.
After three passages and ﬁve months the proportion of
physaliferous cells reached a steady state of approximately
30–40% of cells. Initially, U-CH2 had a doubling time of
about four weeks; after 11 passages, the cells maintained a
doubling time of approximately 1 week.
2.2.2. K-001. Tumor tissue was obtained from a male
patient with recurrent sacral chordoma and was cultured
as described above. The patient provided informed consent
under an IRB-approved study.
2.3. Chordoma Tissue Procurement. RNA from four chor-
doma tumor samples was obtained from Ardais Corporation
(Lexington, MA). The patients were a 59-year-old woman
with a local sacral tumor, a 52-year-old woman with a
local sacral tumor, a 48-year-old man with a local tumor
involving the retrorectal tissue, and a 76-year-old man with
a metastasis to the arm. Tumor cells comprised 70 to 90% of
the tissue sample, and no necrosis was present.
2.4. RNA Isolation and cDNA Generation. Media was aspi-
rated from the ﬂasks, cells were washed twice with PBS
solution in situ, detached with trypsin/EDTA (Sigma catalog
number T4049), and collected following two PBS washes
as a cell pellet. Total RNA was puriﬁed from the pel-
let using the QIAGEN RNeasy mini kit (Qiagen, Valen-
cia, CA) and QIAshredder homogenizer according to the
manufacturer’s instructions. Genomic DNA contamination
waseliminated byDNasedigestiononthecolumnduringthe
isolation as per Qiagen’s instructions. RNA was eluted into
ribonuclease-free water and immediately frozen at −80◦C.
Yield, concentration, and purity as 260/280nM absorbance
ratio was determined on a NanoDrop spectrophotometer
(ThermoScientiﬁc, Waltham, MA). The quality of RNA for
microarray wasanalyzed onanAgilent2100Bioanalyzer,and
only samples with a RIN greater than 7 were used. For RNAs
used for q-RT-PCR, the integrity of the RNA was conﬁrmed
by the ratio of 28S and 18S RNAs visualized under UV
light after separation of denatured RNAs on 1% Tris-Borate-
EDTA agarose gel. RNAswere denatured in 50% formamide,
6% formaldehyde, 10mM sodium phosphate (pH = 7.2),
and 0.5mM EDTA by incubation at 65◦Cf o r5m i n u t e s ,o n e
microgram of ethidium bromide was added to the sample
buﬀer before loading [21]. cDNA was generated from 1-2μg
oftotalRNAusingrandomhexamerprimersandSuperscript
IIIﬁrst-strand synthesis kit(Invitrogen, Carlsbad, CA)as per
the manufacturer’s instructions.
2.5. DNA Isolation. Cultured cells were detached and col-
lected as described above. Cell pellets were immediately
frozen at −80 degrees C and processed later for genomic
DNA isolation using Flexigene DNA isolation kit (Qia-
gen, Valencia, CA) as per the manufacturer’s instructions.
Concentration, size, and integrity of the DNA isolated
were conﬁrmed by NanoDrop spectroscopy, and agarose gel
electrophoresis after ethidium bromide staining.
2.6. Public Data Retrieval. Gene expression array data from
36 diﬀerent types of normal tissue (accession GSE2361) [22]
and four samples of iso-osmotically cultured intervertebral
disc cells (accession GSE1648) [23] were downloaded from
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih
.gov/geo/)GEO.Expressionarray datafrom96mesenchymal
malignancies (experiment E-MEXP-353) [24]w a sd o w n -
loaded from the European Bioinformatics Institution Array-
Express website (http://www.ebi.ac.uk/microarray-as/ae/).
2.7. Gene Expression Analysis. RNA labeling and hybridiza-
tion were performed by the Duke Microarray core facility
as previously described [25] using the HG-U133A and HG-
U133 Plus 2.0 Aﬀymetrix GeneChip platforms, which share
22,277 identical probe sets. All arrays were background
adjusted, quantile normalized, median polished, and log2
transformed using RMA Express [26, 27]. HG-U133A and
HG-U133Plus2.0arraysdata were processedintwoseparate
batches. After RMA normalization, the expression values
for the 22,277 probe sets shared by the two batches were
extracted and combined into a single spreadsheet. In order
to compensate for variations in median signal intensity
between experiments, all arrays were median centered to
zero and standardized to SD = 1[ 28]. Diﬀerential gene
expression was assessed for each probe set using a two-
tailed unequal variance t-test and by absolute diﬀerence in
means between the chordoma set and each other set. An
absolute diﬀerence in means of >2a n dP<.001 were used8 Sarcoma
as criteria for diﬀerential expression. Forgenes with multiple
diﬀerentially expressed probe sets, the mean of the probe
set values was used to represent overall gene expression.
Presence or absence of selected transcripts was determined
using the MAS5 algorithm (GeneChip Operating Software,
Aﬀymetrix).
Unsupervised average linkage hierarchical clustering was
performed using Cluster [29] to determine the similarity of
expression among samples of a set. Two sets were examined;
onesetcontainedchordomastumors,putativechordomacell
lines, and normal tissue (including IVD), and a second set
contained chordoma tumors, putative chordoma cell lines,
and mesenchymal tumors. To remove noise caused by probe
sets with similar expression across all samples, clusteringwas
onlyperformedonprobesetswithstandarddeviationgreater
than 0.7 within a sample set, which resulted in selection of
2351 probe sets for the ﬁrst set of samples and 1208 probe
sets for the second set. Dendrograms and heatmaps were
visualized using TreeView [29].
2.8.Q-RT-PCR ofmRNA Expression and Q-PCR ofGeneCopy
Number. Relative mRNA expression levels were determined
using primers designed for glyceraldehydes 3  phosphate
dehydrogenase (GAPDH; NM 0002046) and the 3  region
of brachyury (T; NM 0003181) using Primer Express 3.0
(Applied Biosystems, Foster City, CA) (see Supplementary
Materials for sequence of oligonucleotides available online
at doi: 10.1155/2010/630129). Quantitation was performed
on an ABI7900 Sequence Detection System (Applied Biosys-
tems). Primers were validated for linear and proportional
ampliﬁcation using U-CH1 cDNA as a positive control for
brachyury expression. For gene copy number, Brachyury-
speciﬁc primers and probe were designed and used for quan-
titation (see Supplementary Materials). RPPH1 and TERT
VIC-labeled TaqMan probes were used for normalization of
input DNA (Applied Biosystems, #4403326 and #4403316,
resp.) in duplex PCR reactions with Brachyury-speciﬁc
primers. All samples were quantitated in quadruplicate.
2.9. Species Analysis. Species of origin of cell lines was
determined by ampliﬁcation of a segment of the aldolase
gene as described previously [30].
2.10.Immunoblot. Proteinextracts ofcellswere generatedby
scraping cells on ice into cold PBS containing phosphatase-
and protease inhibitor cocktails (Calbiochem/EMD, Gibb-
stown, NJ, #524624, and #539134, resp.). Sodium dodecyl
sulfate was added toa ﬁnal concentrationof 1%,and extracts
were immediately denatured by incubation in a boiling-
water bath for 5 minutes. Sample viscosity was reduced by
sonication,andtheproteinconcentrationofeachsamplewas
determined using a BCA protein assay (ThermoScientiﬁc,
Waltham, MA) according to the manufacturer’s instructions.
Five-fold concentrated Laemmli polyacrylamide gel elec-
trophoresis(PAGE)samplebuﬀerwasaddedtogiveaﬁnal1x
concentration. Proteins were separated by PAGE, transferred
to polyvinylidene diﬂuoride membranes, and blocked in
tris-buﬀered saline containing 10% dry milk. Brachyury,
β-actin, cytokeratin, PTEN, phospho-AKT, and AKT were
detected using commercially available antibodies Santa Cruz
biotechnology (Santa Cruz, CA) #SC-17743, #SC-1616, Mil-
lipore (Billerica, MA), MAB1611, Cell Signalling (Danvers,
MA) #9559, #9271, and #9272, respectively, using standard
chemiluminescent detection on X-ray ﬁlm.
2.11. Flow Cytometry. Chordoma cells were harvested from
ﬂasks with 0.05% Trypsin-EDTA, washed with PBS twice,
and resuspended in 1% bovine serum albumin (Sigma,
Cat# A7906, St. Louis, MO) in PBS. Cells were stained
with Phycoerythrin- (PE-) labeled anti-CD24 mAb (BD
Bioscience Pharmingen, Cat# 555428, San Jose, CA) and 7-
AAD (Beckman-Coulter, PN IM3422, Marseille, France) for
30min at 4◦C. PE-labeled mouse IgG1 (BD Bioscience, Cat#
349043) was used for a negative control staining. Cells were
washed with PBS twice, acquired by FACSCalibur machine
(BD Bioscience) and analyzed using CellQuest software
(BD Bioscience). Living (7-AAD-negative) tumor cells were
analyzed for their CD24 expression.
2.12. Immunoﬂuorescence. Following plating on 15mm glass
or thermanox coverslips (Thermo Scientiﬁc, Rochester
NY), U-CH1 and U-CH2 cells were treated with a 3.7%
formaldehyde/phosphate buﬀered saline (PBS) solution for
10 minutes, rinsed brieﬂy with PBS, thenpermeabilized with
1%NonidetP40(FlukaBiochemika)/PBSfor20minutesand
followed with three ﬁve-minute PBS incubations. Brachyury
was detected after sequential one-hour 37◦C incubations
with anti-Brachyury antibody (Santa Cruz, # SC17743) and
antigoat Alexa 488 secondary antibody (Invitrogen) with
three ﬁve-minute room-temperature PBS washes following
each antibody incubation. Antibody dilutions were 1:200
and 1:1500, respectively. Images were obtained on an
Olympus IX51 ﬂuorescent microscope with a DP70 digital
camera attachment.
2.13. STR Genotyping. Genotyping was performed as pre-
viously described (Kelley, 2001) using 10ng of cell line
genomic DNA as template in each 35 cycle PCR reaction.
Genetic marker analysis was performed for the eight STR
markers (CSF1PO, D13S317, D16S539, D5S818, D7S820,
THO1, TPOX, vWA). Seven tumor cell lines of known
genotype and two samples from CEPH family 1331 were
included as controls.
2.14. Array Comparative Genomic Hybridization. Three
micrograms of DNA were fragmented by AluI/RsaI diges-
tion and labeled by random priming incorporating cy5-
dUTP (test sample) or cy3-dUTP (male reference DNA).
Test sample and reference pairs were combined in Agilent
hybridization buﬀer with Agilent blocking agent and Cot-1
DNA and hybridized to oligonucleotide CGH microarrays
for 40 hours at 65◦C (Agilent). For all samples, Agilent
105k microarrays were used except for U-CH1 and U-
CH2, which were hybridized to 244k microarrays. Slides
were washed according to the manufacturer’s protocol, and
imaged with a laser scanner(Agilent).Imageswere processedSarcoma 9
with Agilent Feature Extraction software and segmented in
Nexus software (BioDiscovery). A threshold log2 ratio of .2
or .6 was used for gain or large gain, and −.2 and −1w e r e
used for loss and large loss.
3.Results
3.1. Collection of Existing Cell Lines. We identiﬁed ﬁve
publicationsthatdescribed sevenhuman chordoma cell lines
[11–15]( T a b l e2). No publications describing chordoma cell
lines of nonhuman origin were identiﬁed. Three cell lines
wereprovidedbyChristopherHunter(UniversityofCalgary)
[14, 15], but one line labeled CCL2 died upon arrival and
was not included in any analyses. At the time this study
was conducted, only one of the three cell lines described by
Ricci-Vitiani et al. [13] was provided by the authors. One
cell culture established at Duke University (K001) stopped
growing before analysis could be completed. Images of the
cell lines growing in culture are shown in Figure 1.
3.2. Gene and Protein Expression Analysis. To determine
which putative chordoma cell lines originated from chor-
doma tissue, we compared the global gene expression proﬁle
of the cell lines with four primary chordoma tumors, a set
of ninety-six mesenchymal tumors (which included four
chordomas) [24], thirty-six normal tissue types [22], and
fourprimary short-term culturedintervertebral discsamples
from thecentral nucleuspulposus[23]. The nucleuspulpous
of the IVD is the only adult tissue derived from notochordal
cells, and therefore may represent a nonneoplastic analog
to chordoma [21, 31]. RNA from one cell line, CCL3,
did not hybridize with the array and was, therefore, not
includedin the gene expression analyses. Hierarchical cluster
analysis of the remaining cell lines with the chordoma and
normal tissues (Figure 2) showed that three cell lines, U-
CH1,U-CH2,andK001,were closelyclusteredwiththeeight
chordoma samples in a group distinct from cell lines GB60,
CCL4, and CM-319, and the nonmalignant tissue samples.
The primary bifurcation of the dendrogram separated the
36 normal non-mesenchymal tissues obtain from Ge et al.
from chordoma, IVD, and cell lines, suggesting a possible
batch eﬀect. Next, we examined the expression relationship
of the chordoma samples with mesenchymal tumors [32]
(Figure 3). All of the chordoma tumors clustered together
and away from the mesenchymal tumors except for a
single chordoma tumor, which clustered near an unclassiﬁed
sarcoma sample. Cell lines U-CH1, U-CH2, and K001 were
again clustered closest to the remaining seven chordoma
tumor samples. Three of the chordoma tumor samples that
clustered with U-CH1, U-CH2, and K001 are from the same
data set as the other mesenchymal tumors, thus making a
batch eﬀect unlikely as the sole explanation for the observed
clustering.
Five genes were signiﬁcantly diﬀerentially expressed in
chordoma tumors compared with three control groups
(nonchordoma mesenchymal tumors, normal tissues, and
IVD): T, CD24, COL2A1, CA3, and KRT19 (Supplementary
Materials). Of the six cell lines analyzed, only K001 and
U-CH2 had signiﬁcant expression of all ﬁve genes. U-
CH1 expressed all genes in the signature except for CA3.
CCL4 expressed only KRT19 and CD24, but at levels
33- and 88-fold lower than U-CH2, respectively. CM319
expressed only CD24 and, at a very low level, COL2A1,
while GB60 expressed only low levels of CD24 and COL2A1.
Additional genes diﬀerentiated chordoma tumors from IVD,
normal, and mesenchymal tumors individually but not in all
three comparisons (Supplementary Materials). For example,
KRT15 was diﬀerentially expressed in chordoma versus
mesenchymal tumors and chordoma versus IVD, but not
chordoma versus normal tissue. ACAN, CA12, and RAB3B
were diﬀerentially expressed in chordoma versus normal
tissue and mesenchymal tumors but not IVD.
To conﬁrm the expression of Brachyury and CD24 in
celllines, we performed RT-PCR,immunoblotblot,andﬂow
cytometry.Brachyury mRNAexpressionwasreadilydetected
by quantitative RT-PCR in U-CH1. Using UCH1 as a
standard, Brachyury was expressed 10-fold lower in U-CH2,
160-foldlowerinGB60,andbelowthelimitofdetection(less
than 16,000-fold below U-CH1) in CCL4B and CM319. A
human bronchial epithelial sam p l ew a si n c l u d e da sac o n t r o l
and had Brachyury RNA expressed at 630-fold below U-
CH1. Brachyury protein was detected by immunoblot in U-
CH1 and U-CH2, but was not detected in CM319, CCL4B,
or GB60 (Figure 4(a)). The level of Brachyury protein
expression in U-CH1 was higher than U-CH2, consistent
with the diﬀerence in mRNA expression between these lines
as indicated by qRT-PCR. Immunoﬂuorescence localized
the expression of Brachyury in U-CH1 and U-CH2 to the
nucleus (Figure 4(b)), similar to subcellular localization in
primary chordoma tumors [24]. No staining was seen in
the other cell lines. Secondary antibody alone showed no
staining (data not shown). Using ﬂow cytometry, CD24
protein was detected on the surface of three cell lines, U-
CH1, U-CH2, and CM-319, but not in CCL3, CCL4b, or
GB60 (data not shown). In addition, cytokeratin expression
was used clinically along with other immunohistochemical
markers to determine tissue of origin of tumors. Chordomas
are known to express cytokeratin [33, 34]. CM319, U-
CH1, and U-CH2 showed strong cytokeratin expression by
immunoblot, but no expression was detected in CCL4 and
GB60 cells (Figure 4(c)).
Activation of the PI3K pathway has been implicated in
chordoma pathogenesis and may be a potential therapeutic
target [8, 35]. We examined expression of a key regulatory
protein in this pathway, PTEN, in U-CH1 and U-CH2. As
expected based on PTEN gene loss in U-CH1, no PTEN pro-
teinexpression wasobserved(Figure4(d)).PTEN expression
in U-CH2 was near that found in normal human ﬁbroblasts
(Figure 4(d)). Heterogeneity of expression of PTEN has been
previously described among chordoma tumors (Han 2009),
and we observed corresponding downstream diﬀerences in
phospho-Akt between these two cell lines (Figure 4(e)).
3.3. Array CGH Analysis. aCGH analysis was performed
on six cell lines to determine whether their copy number
aberrations (CNAs) were consistent with that of chordoma
tumors [11, 36]. Cell line CCL3 did not hybridize to the10 Sarcoma
Table 2: Characteristics of cell lines.
Cell line Growth pattern Expression array pattern aCGH Brachyury expression CD24 expression
U-CH1 Physaliferous Chordoma-like Multiple CNV Positive Positive
U-CH2 Physaliferous Chordoma-like Multiple CNV Positive Positive
K001∗ Physaliferous Chordoma-like Positive Positive
CCL3∗∗ Spindle Inadequate Inadequate Negative
CCL4 Spindle Not chordoma-like Normal Negative Negative
GB60 Spindle Not chordoma-like Normal Low RNA; negative protein Negative
CM-319 Polygonal Not chordoma-like Multiple CNV Negative Positive
∗K001 was partially characterized before the cell line was lost
∗∗CCL3 is of nonhuman origin
IVD = intervertebral disc tissue
human aCGH array in two separate attempts and was not
further characterized for CNAs. No CNAs were detected in
cell lines CCL4 and GB60 while U-CH1, UCH-2, and CM-
319 had multiple CNAs (Supplementary Materials), suggest-
ing that only U-CH1, U-CH2, and CM-319 are derived from
tumor cells. Both U-CH1 and U-CH2 showed biallelic loss
of the CDKN2A and CDKN2B loci on chromosome 9p21
(Figure 5). This deletion also encompassed the entire MTAP
locus in U-CH1 and is deleted to near the MTAP locus in U-
CH2. CNAs within this chromosomal region in U-CH1 and
U-CH2 were conﬁrmed by PCR ampliﬁcation using primers
at the 5  and 3  ends of the MTAP gene, and within the
CDKN2A and DMRTA1 genes (Supplementary Materials).
Both the Rb locus on chromosome 13 and the PTEN locus
onchromosome 10had lossinU-CH1,butnotU-CH2(data
not shown). Consistent with this result, the PTEN transcript
was not detected by gene expression microarray in U-CH1,
butwaspresentinU-CH2andtheothercelllinesandtumors
(Supplementary Materials). No chromosomal regions of
high-level ampliﬁcation were found. U-CH1 had numerous
CNAs with losses on chromosomes 1, 3, 4, 9, 10, 11, 13, 18,
and 22, as well as gains on chromosomes 1,7,9,14,15,17,18,
and 19 (Supplementary Materials). U-CH2 had losses on 1p,
2, 3, 4, 8,10,14,16,17,19,20, and X; gains were observed on 1,
6, 7, 12, 15, 16, 19, and X (Supplementary Materials).
3.4. Brachyury Copy Number. We recently described an
increase incopynumberoftheBrachyury gene,T,in families
with predisposition to chordoma [37]. We, therefore, per-
formed quantitative PCR using a T gene exon 6 probe on cell
lines U-CH1 and U-CH2 that were found by aCGH to have
multiple CNAs.aCGH showed CNAin the region of RPPH1,
which is often used as a control in qPCR; therefore, we used
TERT as the control, which did not appear to have CNA on
aCGH. U-CH1 showed qPCR relative value of 1.11 (range:
0.93to1.40)comparedtoTERT, indicating thatU-CH1does
not have an extra copy of the T gene, and consistent with
the aCGH that shows no gain in the 6q region. U-CH2 had
values of 1.36 (range: 1.28 to 1.53), suggesting U-CH2 has
three copies of T, which is consistent with aCGH showing
gain on the telomeric end of 6q (Supplementary Materials).
3.5. Species Analysis. Because CCL3 did not hybridize with
either the expression or the aCGH array, we considered
that it might not be of human origin. To determine the
species of origin, we used PCR to amplify a segment of the
aldolase gene that results in species-speciﬁc PCR product
lengths[30].AnEpstein-Barrvirustransformedlymphoblast
genomicDNAsamplefromaCEPHfamilyindividual,CEPH
1331-01, was used as a control, and it generated the expected
500 and 300bp fragments while CCL3 and a mouse genomic
DNA sample from cultured NIH-3T3 mouse cells resulted
in an identical pattern of a predominant 180bp fragment
and two larger faint bands (Figure 6). All other cell line
samples gave similar amplicons as found for CEPH 1331-01,
thusconﬁrming theirhuman origin. Sequenceanalysis ofthe
180bp fragment from CCL3 conﬁrmed its origin from mice.
3.6. Genotyping. Because cell line identity has often been
confused in laboratories, we performed genotyping of eight
STR markers from the CODISpanel for cell lines U-CH1,U-
CH2,andCM-319(Table 3),as well as CCL4andGB60(data
not shown). The genetic proﬁle of these lines was not found
in the ATCC STR genotype database of cell lines, indicating
they are not derived from common existing cell lines.
4.Discussion
Based on our comprehensive characterization, only one of
ﬁve chordoma cell lines previously described in the literature
has molecular, genetic, and morphological features typical
of chordoma. We also report the creation of a new cell line,
called U-CH2, which exhibits chordoma-like characteristics.
An additional cell line, K001, was grown for over a year
in culture and maintained chordoma-like gene expression
patterns, but has since stopped growing and is no longer
available.
One putative cell line, CCL3, was found to be of murine
origin. All other cell lines were conﬁrmed to be human and
have genotypes distinct from those of commonly used cell
lines in the ATCC repository indicating that they are likely to
be independently derived. However, neither GB60 nor CCL4
have genetic alterations typical of human cancer, suggesting
they may be immortalized clones of nonmalignant cells. At
a minimum, because all chordomas previously analyzed by
array CGH harbored multiple copy number abnormalities
[36], the lack of copy number aberrations indicates that
GB60 and CCL4 are unlikely to be chordoma tumor cells.Sarcoma 11
Table 3: STR Genotype of Three Putative Chordoma Cell Lines.
Cell line CSF1PO D13S317 D16S539 D5S818 D7S820 THO1 TPOX vWA
U-CH1 10,11 11,13 12,13 11,12 9,12 7 8,11 17
U-CH2 11,12 11 12 10,11 8,12 6,9.3 8 17
CM-319 9,10 12,13.3 9,10 11,12 8,12 7 8,12 16,18
It is possible that these cell lines originate from stromal
cells involved in the tumors from which they were cultured.
Furthermore, only U-CH1 and U-CH2 maintain the physal-
iferous cell morphology typical of chordoma tumors.
Hierarchical clustering revealed that the global gene
expression proﬁles of U-CH1, U-CH2, and K001 are highly
similar to that of chordoma tumors, while the remaining cell
lines clustered apart from chordoma tumors. In addition,
we identiﬁed ﬁve genes that were signiﬁcantly diﬀerentially
expressed between chordoma tumors and 92 other mes-
enchymal tumors, 36 normal tissue types, and intervertebral
disc(IVD)tissue.Allﬁveofthesegeneswerehighlyexpressed
in K001 and U-CH2, four were highly expressed in U-
CH1, one was weakly expressed in CM319, and none were
expressed in GB60 or CCL4. The protein products of two
of these genes, T (Brachyury) and CD24 (HSA, heat stable
antigen), are used as diagnostic markers of chordoma [38]
and were therefore measured using biochemical approaches.
Brachyury protein was detected only in U-CH1 and U-CH2,
while CD24 protein was detected in U-CH1, U-CH2, and
CM319.
Based on these observations, we conclude that only U-
CH1 and U-CH2 faithfully maintain the morphology, gene
expression proﬁle, and genomic alterations characteristic of
chordoma tumors. CM319 does not appear physaliferous
and does not express most genes typically expressed by
chordoma tumors; however, it has abnormal genetics consis-
tent with being a cancer cell line and expresses CD24. We,
therefore, cannot conclusively rule out the possibility that
it was derived from chordoma cells. It is conceivable that
CM319 comes from a dediﬀerentiated or atypical chordoma,
or that its gene expression changed signiﬁcantly in culture.
On the other hand, CD24 is expressed at the surface of
cellular subsets of neural lineage diﬀerentiation [33]a n d
has been reported in a number of tumor types [39], so
this cell line could have originated from a tumor other
than chordoma, or could have become contaminated with
another cancer cell line that has not been genotyped by
ATCC. To avoid misidentiﬁcation of chordoma-like cell lines
(U-CH1and U-CH2)in future publications, we recommend
genetic veriﬁcation of cell line identity using the genotype
information reported here.
We found that three cell lines reported in the literature,
CCL3, CCL4, and GB60, are either contaminated or estab-
lished from nonchordoma cells. CCL4and GB60may indeed
be derived from cell populations contained in a chordoma
tumor, but are most likely not neoplastic chordoma cells.
Use of these cell lines has already been reported in several
publications [10, 13–15, 40]. Our ﬁndings call into question
the relevance of results generated using these cell lines to
chordoma.
Because chordoma cells are very slow-growing (doubling
time >5 days), chordoma cell cultures may be particularly
susceptible to overgrowth by immortalized stromal cells or
contamination withfast-growing celllines. Thus,we propose
the following criteria for determining whether a cell line is of
chordoma origin.
4.1. Morphology. Chordoma tumors are comprised of
morphologically heterogeneous cells, including vacuolated
physaliferous cells, small stellate cells, and various other
cell types [35]. Others have reported that chordoma cell
cultures reﬂect a similar degree of morphological hetero-
geneity, with the proportion of physaliferous cells changing
over time [41, 42]. In addition to the cell lines reported
herein, we have attempted to culture ﬁve other chordoma
tumors, and, in each case, over time the physaliferous cells
were replaced by fusiform or spindle-like cells before the
culture ultimately stopped growing. It is not clear whether
the physaliferous cells changed in appearance, or whether
the fusiform cell populations outgrew the physaliferous
cells. Furthermore, it is unknown which cell population(s)
represent the neoplastic cells driving the tumor. Murad
and colleagues found mitoses exclusively in the stellate cell
population, and suggested that stellate cells are the primary
neoplastic cells, perhaps diﬀerentiating into physaliferous
cells [43]. Indeed, dediﬀerentiated chordomas, which have
much higher mitotic activity than conventional chordomas,
are characterized by an absence of physaliferous cells [8].
U-CH1 and U-CH2 consistently maintain approximately
30%–50%physaliferouscells. Based onourobservationsand
the morphological heterogeneity of chordoma cells in vivo,
we do not believe that the absence of physaliferous cells
alone should exclude a cell line from being considered of
chordoma origin; conversely, the presence of physaliferous
cells, a hallmark of chordoma, should be a strong positive
indicator of a chordoma cell line.
4.2. Genetics. Comparative genomic hybridization (CGH)
and array CGH analyses have conﬁrmed that chordomas
are characterized by complex genomes, uniformly possessing
multiple copy number changes and rearrangements [11, 36].
Therefore, chordoma cell lines should also be expected to
uniformly harbor multiple genetic alterations, and cell lines
with no or few genetic alterations are unlikely of chordoma
origin. A cell line is expected to have similar genetic changes
as the originating chordoma tumor. As with other cell lines,
the unique identity of putative chordoma cell lines can be
determined by genotyping, and we recommend the panel of
STR markers used by ATCC. Ideally, the genotype of a cell
line should be demonstrated to be the same as that of the12 Sarcoma
patient from whom the tissue used to derive the line was
obtained.
4.3. Gene and Protein Expression. Of the ﬁve genes we
identiﬁed to be signiﬁcantly overexpressed in chordoma,
Brachyury, a transcription factor present in the nucleus of
notochord cells [44], is the most speciﬁc for chordoma [24].
By immunohistochemistry, Brachyury is highly expressed in
chordoma but not in a wide variety of normal or neoplastic
tissue, andis, therefore,used asa diagnosticmarker forchor-
doma[24].Other than chordomas, only hemangioblastomas
highly express Brachyury [45, 46]. However, recently Palena
and colleagues reported modest Brachyury expression in a
numberofcarcinomas andcarcinoma-derivedcell lines[47].
Therefore, the presence of Brachyury alone is not suﬃcient
to indicate the validity of a chordoma cell line. Conversely,
one study found that only 89% of chordomas expressed
Brachyury [38], suggesting that the absence of Brachyury
expression does not rule out the validity of a chordoma cell
line. Furthermore, the chondrocytic diﬀerentiation potential
of chordoma cells has been previously reported, and it has
beensuggestedthatsomechordomasundergodiﬀerentiation
that mimics the development of the nucleus pulposus [48].
Our analysis, and work of Vujovic and colleagues [24],
demonstrated that Brachyury is not expressed in nucleus
pulposus cells which are derived from the notochord [31],
suggesting that cells of notochordal origin, and presumably
chordoma, can lose Brachyury expression.
For cell lines that lack Brachyury but have abnormal
genetics (like CM319), expression of one or more markers
of chordoma including CD24, collagen type II alpha 1,
keratin 19, and carbonic anhydrase 3 could oﬀer evidence
of chordoma-derived cells. If material from the original
tumor is available, expression of these genes should be
compared between the tumor and cell line to determine if
expression levels changed in vitro. Cluster analysis of global
gene expression may be required to further deﬁne the likely
origin of a non-Brachyury expressing cell line.
Our study has several limitations. First, we were unable
to compare the cell lines with the tumors from which they
were derived. Furthermore, we are unable to apply a tissue
of origin analysis because the normal tissue from which
chordoma is thought to be derived, the notochord, is not
available to us for expression analysis. However, our cluster
analysis demonstrates thatthe cell lines U-CH1,U-CH2,and
K 0 0 1a r el i k e l yt os h a r et h es a m et i s s u eo fo r i g i n .S e c o n d ,a l l
existing cell lines have been derived from chordomas arising
in the sacrum. Indeed, the majority of biological analyses
of chordoma have been done on sacral chordoma, which
present as much larger tumors. Thus, it is unknown whether
chordomasarising in clivusorotherareas can bemodeled by
chordoma cell lines of sacral origin.
5.Conclusions
In summary, two cell lines, U-CH1 and U-CH2, have
characteristics consistent with chordoma origin and are
available for use as models of chordoma. One or both of
these cell lines have molecular properties that could model
speciﬁc therapeutic targets such as p16 deletion [36], MTAP
deletion [9], PTEN inactivation [8, 49], and Brachyury gene
duplication [37]. Published results using the other cell lines
studied may not be relevant to human chordoma.
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